Tranexamic Acid NDC 72319-028

NDC codes

FDA NDC Directory

Product NDC (as listed)72319-028Labeler and product segments. Claims need a package NDC.

Product NDC at billing width72319-0028Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
72319-028-01	72319002801	30 TABLET in 1 BOTTLE, PLASTIC (72319-028-01)Marketed from Jun 30, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Tranexamic Acid
Generic name (nonproprietary): tranexamic acid
Active ingredients: Tranexamic acid — 650 mg/1
Dosage form: Tablet
Route: Oral
Labeler: i3 Pharmaceuticals, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 219702
Marketing start: Jun 30, 2026
Listing expires: Dec 31, 2027
Other FDA classes: Decreased Fibrinolysis (Physiologic effect)
Identifiers: Product ID 72319-028_5569a8fa-e383-ff40-e063-6394a90a456dSPL ID 5569a8fa-e383-ff40-e063-6394a90a456dSPL set ID 2c48c13a-5e7d-43ef-81a3-27d3bcda0f80RxCUI 883826UNII 6T84R30KC1UPC 0372319028014
Pharmacologic class: Antifibrinolytic Agent

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N472319002801 followed by a unit qualifier and the quantity

Package 72319-0028-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 29, 2026.

Indications (excerpt from the label)

Tranexamic acid tablets are indicated for the treatment of cyclic heavy menstrual bleeding in females of reproductive potential [see Clinical Studies (14) ]. Tranexamic acid tablets is an antifibrinolytic indicated for the treatment of cyclic heavy menstrual bleeding in females of reproductive potential. ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)